News & Updates

Show Multimedia Only
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial

Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial

25 Feb 2022

Use of famotidine in the treatment of outpatients with mild-to-moderate COVID-19 is safe and well tolerated, leading to rapid resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity, according to the results of a phase II trial.

25 Feb 2022
Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients

Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients

24 Feb 2022 byChristina Lau

Patients with non-severe coronavirus disease 2019 (COVID-19) who have worse glycaemic status are more likely to deteriorate clinically, but glycaemic status does not adversely impact neutralizing antibody (NAb) responses, researchers from the University of Hong Kong have shown.

24 Feb 2022
Booster dose effective in reducing COVID-19 across ages in adults

Booster dose effective in reducing COVID-19 across ages in adults

23 Feb 2022 byRoshini Claire Anthony

The risk of COVID-19 is substantially reduced in adults who receive a third “booster” dose of the BNT162b2 vaccine regardless of their age, according to a study from Israel.

23 Feb 2022
Why do some PCR-negative patients test positive on COVID-19 blood tests?

Why do some PCR-negative patients test positive on COVID-19 blood tests?

22 Feb 2022 byTristan Manalac

Serological assays for the coronavirus disease 2019 (COVID-19) sometimes show contradictory findings when compared with nasopharyngeal swab polymerase chain reaction (PCR) tests, according to a recent Singapore study. In particular, even PCR-negative patients with no known exposure could test positive for antibodies.

22 Feb 2022